This company has been marked as potentially delisted and may not be actively trading.

Amicus Therapeutics (FOLD) Competitors

FOLD vs. NBIX, IONS, MDGL, EXEL, and BMRN

Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

How does Amicus Therapeutics compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Neurocrine Biosciences had 41 more articles in the media than Amicus Therapeutics. MarketBeat recorded 42 mentions for Neurocrine Biosciences and 1 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.11 beat Neurocrine Biosciences' score of 0.63 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	12 Very Positive mention(s)	3 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.6% of Neurocrine Biosciences shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neurocrine Biosciences has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.29	$478.60M	$6.49	23.21
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A

Neurocrine Biosciences has a net margin of 21.55% compared to Amicus Therapeutics' net margin of -4.27%. Neurocrine Biosciences' return on equity of 19.79% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Amicus Therapeutics	-4.27%	4.15%	1.09%

Neurocrine Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Neurocrine Biosciences presently has a consensus target price of $184.15, suggesting a potential upside of 22.25%. Amicus Therapeutics has a consensus target price of $14.56, suggesting a potential upside of 0.50%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.82
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Neurocrine Biosciences beats Amicus Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Amicus Therapeutics compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Ionis Pharmaceuticals had 12 more articles in the media than Amicus Therapeutics. MarketBeat recorded 13 mentions for Ionis Pharmaceuticals and 1 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.11 beat Ionis Pharmaceuticals' score of 0.66 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Amicus Therapeutics has lower revenue, but higher earnings than Ionis Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	13.20	-$381.39M	-$2.07	N/A
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A

Amicus Therapeutics has a net margin of -4.27% compared to Ionis Pharmaceuticals' net margin of -30.91%. Amicus Therapeutics' return on equity of 4.15% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%
Amicus Therapeutics	-4.27%	4.15%	1.09%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ionis Pharmaceuticals presently has a consensus target price of $99.35, suggesting a potential upside of 31.80%. Amicus Therapeutics has a consensus target price of $14.56, suggesting a potential upside of 0.50%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Ionis Pharmaceuticals is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Ionis Pharmaceuticals beats Amicus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Amicus Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Madrigal Pharmaceuticals had 20 more articles in the media than Amicus Therapeutics. MarketBeat recorded 21 mentions for Madrigal Pharmaceuticals and 1 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.11 beat Madrigal Pharmaceuticals' score of 0.34 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Amicus Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$1.13B	10.12	-$288.28M	-$12.80	N/A
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A

Amicus Therapeutics has a net margin of -4.27% compared to Madrigal Pharmaceuticals' net margin of -27.32%. Amicus Therapeutics' return on equity of 4.15% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-27.32%	-50.15%	-25.44%
Amicus Therapeutics	-4.27%	4.15%	1.09%

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Madrigal Pharmaceuticals presently has a consensus target price of $682.07, suggesting a potential upside of 37.23%. Amicus Therapeutics has a consensus target price of $14.56, suggesting a potential upside of 0.50%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Madrigal Pharmaceuticals beats Amicus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Amicus Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Exelixis had 51 more articles in the media than Amicus Therapeutics. MarketBeat recorded 52 mentions for Exelixis and 1 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.11 beat Exelixis' score of 0.65 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	18 Very Positive mention(s)	9 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Exelixis has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.26	$782.57M	$3.01	16.51
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A

Exelixis has a net margin of 35.08% compared to Amicus Therapeutics' net margin of -4.27%. Exelixis' return on equity of 39.89% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Amicus Therapeutics	-4.27%	4.15%	1.09%

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exelixis presently has a consensus target price of $47.83, suggesting a potential downside of 3.78%. Amicus Therapeutics has a consensus target price of $14.56, suggesting a potential upside of 0.50%. Given Amicus Therapeutics' higher possible upside, analysts plainly believe Amicus Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

Exelixis beats Amicus Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Amicus Therapeutics compare to BioMarin Pharmaceutical?

Amicus Therapeutics (NASDAQ:FOLD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, BioMarin Pharmaceutical had 27 more articles in the media than Amicus Therapeutics. MarketBeat recorded 28 mentions for BioMarin Pharmaceutical and 1 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.11 beat BioMarin Pharmaceutical's score of 0.20 indicating that Amicus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amicus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	6 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical has a net margin of 8.29% compared to Amicus Therapeutics' net margin of -4.27%. BioMarin Pharmaceutical's return on equity of 6.50% beat Amicus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-4.27%	4.15%	1.09%
BioMarin Pharmaceutical	8.29%	6.50%	5.07%

Amicus Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Amicus Therapeutics currently has a consensus target price of $14.56, suggesting a potential upside of 0.50%. BioMarin Pharmaceutical has a consensus target price of $89.91, suggesting a potential upside of 71.00%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	1 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.08
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.74

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioMarin Pharmaceutical has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$634.21M	7.17	-$27.11M	-$0.08	N/A
BioMarin Pharmaceutical	$3.24B	3.13	$348.90M	$1.37	38.38

Summary

BioMarin Pharmaceutical beats Amicus Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Amicus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FOLD vs. The Competition

Export

Metric	Amicus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.55B	$3.37B	$6.18B	$12.27B
Dividend Yield	N/A	2.24%	2.78%	5.22%
P/E Ratio	-181.13	15.19	20.66	25.70
Price / Sales	7.17	194.53	527.64	64.90
Price / Cash	234.67	56.93	27.81	36.27
Price / Book	16.66	6.94	9.77	6.74
Net Income	-$27.11M	$24.11M	$3.54B	$333.09M

Amicus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FOLD Amicus Therapeutics	1.0945 of 5 stars	$14.49 flat	$14.56 +0.5%	+142.3%	$4.55B	$634.21M	N/A	480	High Trading Volume
NBIX Neurocrine Biosciences	3.0659 of 5 stars	$134.07 +1.7%	$180.45 +34.6%	+31.6%	$13.25B	$2.86B	28.77	2,000	Analyst Forecast
IONS Ionis Pharmaceuticals	3.7322 of 5 stars	$75.45 +0.2%	$99.35 +31.7%	+134.7%	$12.44B	$944M	N/A	1,402
MDGL Madrigal Pharmaceuticals	2.995 of 5 stars	$518.66 +1.0%	$685.31 +32.1%	+73.1%	$11.84B	$958.40M	N/A	90	Earnings Report Analyst Revision
EXEL Exelixis	3.0405 of 5 stars	$44.17 +1.1%	$47.00 +6.4%	+33.1%	$11.10B	$2.32B	15.95	1,077	Earnings Report Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FOLD) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amicus Therapeutics (FOLD) Competitors

FOLD vs. NBIX, IONS, MDGL, EXEL, and BMRN

How does Amicus Therapeutics compare to Neurocrine Biosciences?

Summary

How does Amicus Therapeutics compare to Ionis Pharmaceuticals?

Summary

How does Amicus Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Amicus Therapeutics compare to Exelixis?

Summary

How does Amicus Therapeutics compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOLD vs. The Competition

Amicus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amicus Therapeutics (FOLD) Competitors

FOLD vs. NBIX, IONS, MDGL, EXEL, and BMRN

How does Amicus Therapeutics compare to Neurocrine Biosciences?

Does the media prefer NBIX or FOLD?

Do institutionals & insiders have more ownership in NBIX or FOLD?

Which has higher earnings & valuation, NBIX or FOLD?

Is NBIX or FOLD more profitable?

Which has more risk and volatility, NBIX or FOLD?

Do analysts prefer NBIX or FOLD?

Summary

How does Amicus Therapeutics compare to Ionis Pharmaceuticals?

Does the media prefer IONS or FOLD?

Which has more risk and volatility, IONS or FOLD?

Which has higher earnings & valuation, IONS or FOLD?

Is IONS or FOLD more profitable?

Do institutionals & insiders have more ownership in IONS or FOLD?

Do analysts prefer IONS or FOLD?

Summary

How does Amicus Therapeutics compare to Madrigal Pharmaceuticals?

Does the media favor MDGL or FOLD?

Which has more volatility & risk, MDGL or FOLD?

Which has stronger earnings and valuation, MDGL or FOLD?

Is MDGL or FOLD more profitable?

Do insiders and institutionals hold more shares of MDGL or FOLD?

Do analysts prefer MDGL or FOLD?

Summary

How does Amicus Therapeutics compare to Exelixis?

Does the media favor EXEL or FOLD?

Which has more volatility & risk, EXEL or FOLD?

Which has stronger earnings and valuation, EXEL or FOLD?

Is EXEL or FOLD more profitable?

Do insiders and institutionals hold more shares of EXEL or FOLD?

Do analysts prefer EXEL or FOLD?

Summary

How does Amicus Therapeutics compare to BioMarin Pharmaceutical?

Does the media refer more to FOLD or BMRN?

Is FOLD or BMRN more profitable?

Which has more volatility & risk, FOLD or BMRN?

Do analysts recommend FOLD or BMRN?

Do institutionals and insiders hold more shares of FOLD or BMRN?

Which has preferable valuation and earnings, FOLD or BMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FOLD vs. The Competition

Amicus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools